ストックスクリーナーアプリを入手
2.65
0.76%
0.02
アフターアワーズ：
2.65
前日終値:
$2.63
開ける：
$2.64
24時間の取引高:
1.18M
Relative Volume:
1.17
時価総額：
$114.24M
収益：
$51.13M
当期純損益:
$-93.80M
株価収益率:
-1.1883
EPS:
-2.23
ネットキャッシュフロー:
$-129.10M
1週間 パフォーマンス:
+2.71%
1か月 パフォーマンス:
+3.11%
6か月 パフォーマンス:
+69.87%
1年 パフォーマンス:
+130.43%
1日の値動き範囲:
$2.62
$2.65
1週間の範囲:
$2.56
$2.65
52週間の値動き範囲:
$0.89
$2.66
Repare Therapeutics Inc Stock (RPTX) Company Profile
名前
Repare Therapeutics Inc
セクター
電話
(857) 412-7018
住所
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
2.65 | 113.37M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-06-09 | アップグレード | Stifel | Hold → Buy |
| 2023-02-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 開始されました | CapitalOne | Overweight |
| 2022-04-12 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-17 | 再開されました | Goldman | Buy |
| 2021-09-23 | 開始されました | Stifel | Buy |
| 2021-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-28 | 開始されました | Guggenheim | Buy |
| 2021-03-01 | 開始されました | Berenberg | Buy |
| 2020-10-28 | 開始されました | Northland Capital | Outperform |
| 2020-07-14 | 開始されました | Cowen | Outperform |
| 2020-07-14 | 開始されました | Goldman | Neutral |
| 2020-07-14 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-14 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Repare Therapeutics Inc (RPTX) 最新ニュース
Repare Shareholders Approve Acquisition by XenoTherapeutics - citybiz
Repare Shareholders approve acquisition by XenoTherapeutics - Medical Buyer
Repare Therapeutics (RPTX) Shareholders Approve Acquisition by X - GuruFocus
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - Investing News Network
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics - TipRanks
99.76% of Repare voters back takeover by nonprofit XenoTherapeutics - Stock Titan
Bank Watch: Is Repare Therapeutics Inc stock heavily shorted2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update - MarketBeat
Update Report: Is Repare Therapeutics Inc stock heavily shorted2025 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4%Here's Why - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% – Here’s Why - Defense World
Levels Update: Is Repare Therapeutics Inc. stock a top pick in earnings season2025 Sector Review & Daily Stock Trend Watchlist - Bộ Nội Vụ
Aug Opening: Will Repare Therapeutics Inc stock attract ESG investorsMarket Sentiment Summary & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Insider Trends: Why Repare Therapeutics Inc. stock is in analyst buy zonePortfolio Update Report & Capital Efficient Trading Techniques - Bộ Nội Vụ
Published on: 2026-01-13 02:16:07 - baoquankhu1.vn
What catalysts could drive Repare Therapeutics Inc. stock higherTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Oklahoma City NewsThe OklahomanRepare Therapeutics Inc.Common Shares (Nasdaq:RPTX) Stock Quote - FinancialContent
Is Repare Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Review & Risk Managed Trade Strategies - Улправда
Can Repare Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Will Repare Therapeutics Inc. stock benefit from commodity prices2025 Big Picture & Momentum Based Trading Signals - ulpravda.ru
Repare Therapeutics sells RP-3467 cancer program assets to Gilead for up to $30 million - MSN
Can Repare Therapeutics Inc. stock double in next 5 yearsVolatility Adjusted Trading & Learn to Trade with Real-Time Feedback - Улправда
Repare Therapeutics Inc.Common Shares (NQ: RPTX - FinancialContent
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
PYXS,RPTX Dividends - Finviz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout - TipRanks
RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug - MSN
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Nigeria
Repare’s Sale Sparks Concerns: Time to Sell? - StocksToTrade
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX) - MarketBeat
Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million - El-Balad.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Repare Therapeutics Faces Scrutiny Amid Sale Deal - timothysykes.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead - GuruFocus
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln - Nasdaq
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Repare Therapeutics Inc (RPTX) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):